TCL Archive FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says. April 1, 2005
TCL Archive DCT Board Okays Extension Of Phase 1 Master Agreements, Increase To $4 Million February 27, 1987
TCL Archive Conversation with The Cancer Letter: UT System Vice Chancellor Shine Describes Rationale for Granting Waiver to DePinho October 26, 2012
TCL Archive In Brief Election Results Won’t Hurt Cancer Program, May Help; Coper To Stay If Carter Wants Him November 12, 1976
TCL Archive In Their Own Words: A 64-page Internal Report with over 1,500 Faculty Comments on MD Anderson Morale March 29, 2013
